BRIGHT MINDS BIOSCIENCES INC. (DRUG) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$61.31

From 52W high−36.47%

Volume142282.00

Market cap$598.34M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$61.31

From 52W high

−36.47%

Volume

142282.00

Market cap

$598.34M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−15.6x

P/E (TTM)

—

RSI (14)

32.8

MomentumView details →

1D Return

−0.93%

YTD Return

−21.95%

SummaryUpdated Jun 1, 2026

Bright Minds Biosciences Inc. (NASDAQ:DRUG) is a pre-clinical stage biotechnology company founded in 2019 and headquartered in Vancouver, Canada. The company went public in March 2021 and focuses on developing novel serotonin-based medicines for patients with severe neurological and psychiatric conditions. As a pre-clinical biotech firm, Bright Minds has not yet generated revenue from product sales and remains in the research and development phase of bringing potential treatments to market.

Ask drillr about BRIGHT MINDS BIOSCIENCES INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−15.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.7x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−8.03%

ROA (TTM)

−7.96%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−77.05%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−0.93%

YTD Return

−21.95%

1Y Return

+14.32%

RSI (14)

32.8

vs 50D SMA

−17.01%

vs 200D SMA

−21.77%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

121.97x

Quick Ratio

121.97x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.17

EPS Surprise

86.10%

Beats (12Q)

6/12

Next Q EPS Est

−$1.08

Avg Surprise (4Q)

46.93%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−24.75M

Op. CF (TTM)

−25.00M

Next earningsDec 22, 2026 →

Latest newsMore news →

Vistagen Therapeutics appointed Douglas J. Williamson, M.D. as a director, effective July 29, 2026, with stock option compensation and eligibility for the Director Compensation Plan.52d ago

Similar companies

AgomAb Therapeutics N.V. American Depositary SharesAGMB CytomX Therapeutics, Inc.CTMX CorMedix Inc.CRMD Shattuck Labs, Inc.STTK Phathom Pharmaceuticals, Inc.PHAT 3D Medicines Inc.01244.HK Find similar companies →

Latest newsMore news →

Vistagen Therapeutics appointed Douglas J. Williamson, M.D. as a director, effective July 29, 2026, with stock option compensation and eligibility for the Director Compensation Plan.52d ago